WO1997047271A3 - Cellular vaccines and immunotherapeutics and methods for their preparation - Google Patents

Cellular vaccines and immunotherapeutics and methods for their preparation Download PDF

Info

Publication number
WO1997047271A3
WO1997047271A3 PCT/US1997/010238 US9710238W WO9747271A3 WO 1997047271 A3 WO1997047271 A3 WO 1997047271A3 US 9710238 W US9710238 W US 9710238W WO 9747271 A3 WO9747271 A3 WO 9747271A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunotherapeutics
preparation
methods
cellular vaccines
diseases
Prior art date
Application number
PCT/US1997/010238
Other languages
French (fr)
Other versions
WO1997047271A9 (en
WO1997047271A2 (en
Inventor
Yajun Guo
Original Assignee
Yajun Guo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yajun Guo filed Critical Yajun Guo
Priority to JP50183398A priority Critical patent/JP3676380B2/en
Priority to AU42283/97A priority patent/AU727955B2/en
Priority to EP97940524A priority patent/EP0956046A4/en
Publication of WO1997047271A2 publication Critical patent/WO1997047271A2/en
Publication of WO1997047271A3 publication Critical patent/WO1997047271A3/en
Publication of WO1997047271A9 publication Critical patent/WO1997047271A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells

Abstract

The present invention provides a method for enhancing the immunogenicity of weakly immunogenic or non-immunogenic cells, resulting in a cellular vaccine that can stimulate T cell activation, which in turn leads to an effective immune response. The cellular vaccines of the present invention are useful for the prevention and treatment of diseases which develop and/or persist by escaping the immune response triggered by T cell activation. Such diseases include, for example, all cancers, natural and induced immune deficiency states, and diseases caused by infections with a variety of pathogens.
PCT/US1997/010238 1996-06-12 1997-06-11 Cellular vaccines and immunotherapeutics and methods for their preparation WO1997047271A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP50183398A JP3676380B2 (en) 1996-06-12 1997-06-11 Cellular vaccines and immunotherapeutic agents and methods for their production
AU42283/97A AU727955B2 (en) 1996-06-12 1997-06-11 Cellular vaccines and immunotherapeutics and methods for their preparation
EP97940524A EP0956046A4 (en) 1996-06-12 1997-06-11 Cellular vaccines and immunotherapeutics and methods for their preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1963996P 1996-06-12 1996-06-12
US60/019,639 1996-06-12

Publications (3)

Publication Number Publication Date
WO1997047271A2 WO1997047271A2 (en) 1997-12-18
WO1997047271A3 true WO1997047271A3 (en) 1998-02-12
WO1997047271A9 WO1997047271A9 (en) 1998-03-12

Family

ID=21794256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/010238 WO1997047271A2 (en) 1996-06-12 1997-06-11 Cellular vaccines and immunotherapeutics and methods for their preparation

Country Status (6)

Country Link
EP (1) EP0956046A4 (en)
JP (1) JP3676380B2 (en)
CN (1) CN1221349A (en)
AU (1) AU727955B2 (en)
CA (1) CA2258082A1 (en)
WO (1) WO1997047271A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666609B1 (en) 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
EP1227837B1 (en) * 1999-10-22 2008-05-21 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
DE19957470A1 (en) 1999-11-24 2001-06-21 Actinodrug Pharmaceuticals Gmb Tetrahydropyrimidine dioxygenase gene and method for enzymatic in vivo and in vitro production of hydroxylated tetrahydropyrimidines
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10156482A1 (en) 2001-11-12 2003-05-28 Gundram Jung Bispecific antibody molecule
EP1504037B1 (en) * 2002-05-10 2009-12-30 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
EP2377549A1 (en) * 2002-06-07 2011-10-19 ZymoGenetics, Inc. Use of IL-21 for treating viral infections
WO2008100598A2 (en) * 2007-02-15 2008-08-21 Mannkind Corporation A method for enhancing t cell response
EP3320912B1 (en) 2008-04-17 2021-03-31 IO BIOTECH ApS Indoleamine 2, 3-dioxygenase based immunotherapy
CN105925544A (en) * 2016-06-27 2016-09-07 武汉思安医疗技术有限公司 Preparation method and application of 4-1BB-containing lentivirus
AU2018281830B2 (en) * 2017-06-09 2023-11-02 Agonox, Inc. Utilization of CD39 and CD103 for identification of human tumor reactive cells for treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844893A (en) * 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844893A (en) * 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLOOD, 15 May 1996, Vol. 87, No. 10, DEMANET et al., "Bispecific Antibody-Mediated Immunotherapy of the BCL1 Lymphoma: Increased Efficacy with Multiple Injections and CD28-Induced Costimulation", pages 4390-4398. *
CANCER RESEARCH, 15 September 1992, Vol. 52, AZUMA et al., "Induction of Intercellular Adhesion Molecule 1 on Small Cell Carcinoma Cell Lines by Gamma-Interferon Enhances Spontaneous and Bispecific Anti-CD3 X Antitumor Antibody-Directed Lymphokine-Activated Killer Cell Cytotoxicity", pages 4890-4894. *
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, May 1997, Vol. 108, HOMBACH et al., "Specific Activation of Resting T Cells Against Tumour Cells by Bispecific Antibodies and CD28-Mediated Costimulation is Accompanied by Th1 Differentiation and Recruitment of MHC-Independent Cytotoxicity", pages 352-357. *
NATURE MEDICINE, April 1997, Vol. 3. No. 4, GUO et al., "Effective Tumor Vaccines Generated by In Vitro Modification of Tumor Cells with Cytokines and Bispecific Monoclonal Antibodies", pages 451-455. *
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, March 1996, Vol. 37, SHI et al., "Adoptive Immunotherapy for Hepatocellular Carcinoma with Tumor Specific CTLs Generated in Vitro by Stimulating TILs or PBLs with the Cytokine Treated Tumor Cells and a Bispecific Monoclonal Antibody", page 480, Abstract *
SCIENCE, 06 May 1994, Vol. 264, RENNER et al., "Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells", pages 833-835. *

Also Published As

Publication number Publication date
CN1221349A (en) 1999-06-30
JPH11514666A (en) 1999-12-14
EP0956046A4 (en) 2004-10-20
WO1997047271A2 (en) 1997-12-18
EP0956046A2 (en) 1999-11-17
CA2258082A1 (en) 1997-12-18
AU4228397A (en) 1998-01-07
JP3676380B2 (en) 2005-07-27
AU727955B2 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
IL145982A0 (en) Vaccines
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
WO1999002186A3 (en) Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
WO1999041369A3 (en) Genetic vaccine vector engineering
MY125202A (en) Vaccine
WO1999055730A3 (en) Polyepitope carrier protein
CA2033640A1 (en) Vaccines against cancer and infectious diseases
WO2002034205A3 (en) Using heat shock proteins to increase immune response
WO2004058157A3 (en) Yeast-based vaccines as immunotherapy
EP0370573A3 (en) Skin test and test kit for aids
DE69929232D1 (en) VIRUSELY PARTICLES FOR INDUCING AUTOANTIC BODIES
PT1104306E (en) CPG COMPOSITIONS AND SAPONIN ADJUVANTS AND THEIR METHODS
WO1997047271A3 (en) Cellular vaccines and immunotherapeutics and methods for their preparation
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
BR9610679A (en) Leishmania antigens for use in leishmaniasis therapy and dysgnosis
NZ309713A (en) Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine
WO2005007673A3 (en) Immunogenic peptides
HUP9801223A2 (en) Method for enhancing the antibody response to specific antigens with interleukin-10
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
MXPA02010173A (en) Leishmania.
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
WO2002070004A3 (en) Papillomavirus vaccines
WO2001043772A3 (en) Method and device for producing an autologous immunization vaccine against cancerous diseases (tumour vaccine)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97195438.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES BEARING THE SAME NUMBER; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2258082

Country of ref document: CA

Ref document number: 2258082

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1998 501833

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997940524

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997940524

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997940524

Country of ref document: EP